AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor, M.D., the Company’s newly-appointed Chief Medical Officer.
The inducement awards consist of a non-qualified stock option to purchase 233,333 shares of the Company’s common stock and restricted stock units representing 116,667 shares of the Company’s common stock. The option has an exercise price of $5.36 per share, which is equal to the closing price of the Company’s common stock on the date of grant. The option has a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of Dr. Trenor’s date of hire, or August 24, 2026, and the remainder vesting monthly for three years thereafter. 10,400 restricted stock units vest on January 1, 2027, with the remainder vesting in approximately three equal annual installments beginning January 1, 2028. Vesting is subject to the employee’s continued service with the Company through the applicable vesting dates.
The inducement awards were granted as a material inducement to the employee’s employment and were approved by AN2’s Compensation Committee with a grant date of September 15, 2026, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. The inducement awards were granted pursuant to AN2’s 2026 Employment Inducement Award Plan.
About AN2 Therapeutics
AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical oncology candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.
COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com
INVESTOR AND MEDIA CONTACT:
Anne Bowdidge
ir@an2therapeutics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260916973446/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
What’s Ahead for Stocks This Quarter—and Where to Invest
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
United States